Project Grant R01CA294636
Award Date
8/7/24
Completion Date
7/31/29
Dollars Obligated
$546K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This $521,579 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas Southwestern Medical Center will fund a research project to characterize the role of the hepatic leukemia factor (HLF) in controlling lung metastasis in clear cell renal cell carcinoma (CCRCC). The research aims to: Assess the functional significance of HLF in promoting CCRCC lung metastasis using various in vivo models. Delineate the molecular...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,107,000 three-year Project Grant to The University of Texas Southwestern Medical Center in Dallas, TX. The grant, effective September 1, 2023, will fund research to characterize the epigenetic and metabolic vulnerabilities in clear cell renal cell carcinoma (ccRCC) with VHL gene deficiencies, and explore the therapeutic potential of these findings. The University of Texas System will...
The federal Project Grant award for $443,632.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will fund research by The University of Texas MD Anderson Cancer Center to investigate the tissue-specific effects of VHL germline variants in von Hippel-Lindau syndrome. The two-year project, running from February 1, 2025 to January 31, 2027, aims to advance the understanding of genetic mechanisms underlying this rare, inherited...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
The National Cancer Institute (NCI) awarded a $686,919 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The University of Texas MD Anderson Cancer Center. The grant aims to elucidate the role of T cell ferroptosis, a form of programmed cell death, in renal medullary carcinoma (RMC) through an investigation of 3D chromatin architecture rewiring. The key products and services to be delivered under this 5-year grant include: 1) establishing the connection between altered...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $371,905 will support research at the University of Florida to define the role of angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (CCRCC) progression, metastasis, and tumor vascularization. The objectives are to 1) determine the impact of secreted ANGPTL4 in the tumor microenvironment on CCRCC growth and angiogenesis, 2) evaluate the efficacy of combining anti-ANGPTL4...
This federal Project Grant award for $968,904.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Texas Southwestern Medical Center (UT Southwestern) to target the DNA damage response as a potential treatment for clear cell renal cell carcinoma. The project will be conducted at UT Southwestern's facilities in Dallas, Texas over a 4-year period from July 1, 2024 to June 30, 2028. This...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...
This $172,193 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the Dana-Farber Cancer Institute, Inc. (DFCI) to characterize gene regulatory elements and metabolic pathways in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer. The key goals are to: 1) develop optimization methods to estimate activity of transcription factors driving TRCC, 2) build predictive metabolic models to...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The five-year grant, running from December 1, 2024 to November 30, 2029, will support research to determine how specific configurations of the tricarboxylic acid (TCA) cycle metabolic pathway contribute to the development and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The research aims to...